Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support

American Journal of Hematology

Volumn 82, Issue 12, 2007, Pages 1071-1075

  Vogl, Dan T ^a   Liu, Stephen V ^a   Chong, Elise A ^a   Luger, Selina M ^a   Porter, David L ^a   Schuster, Stephen J ^a   Tsai, Donald E ^a   Perl, Alexander ^a   Loren, Alison W ^a   Goldstein, Steven C ^a   Nasta, Sunita D ^a   Andreadis, Charalambos ^a   Mangan, Patricia A ^a   Hummel, Kimberly ^a   Siegel, Don L ^a   Glatstein, Eli ^a   Stadtmauer, Edward A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; INTERFERON; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 36749027636     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21038     Document Type: Article

References (18)

1. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
3. Kyle RA, Leong T, Li S, et al. Complete response in multiple myeloma. Cancer 2006;106:1958-1966.
4. Sirohi B, Powles R, Kulkarni S, et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 1999;107:656.
5. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-763.
6. Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003;14:1039-1044.
7. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: A Phase III multicenter randomized trial. Cancer 2006;106:848-858.
8. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.
9. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-39.
10. Vogl DT, Luger S, Porter DL, et al. Thalidomide and dexamethasone induction therapy is associated with superior progression-free survival after autotransplant for myeloma. Am Soc Hematol 2005. (Abstract no. 1171).
11. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11:1230-1237.
12. Kumar S, Lacy MQ, Dispenzieri A, et al. Analysis of outcome after autologous stem transplantation in patients with newly diagnosed myeloma: Comparison of different induction regimens. Am Soc Hematol 2006. (Abstract no. 3079).
13. Cavo M, Cellini C, Zamagni E, et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Am Soc Hematol 2004. (Abstract).
14. Attal M, Harousseau J-L, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294.
15. Attal M, Harousseau J-L, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
16. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120.
17. Macro M, Divine M, Uzunhan Y, et al. Dexamethasone+Thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): A randomized trial. Am Soc Hematol 2006. (Abstract no. 57).
18. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1999;102:1115.